Last updated: February 13, 2026
What Is the Drug Identified by NDC 49348-0115?
The National Drug Code (NDC) 49348-0115 corresponds to Sandoz's filgrastim-sndz (Zarxio). It is a biosimilar to Amgen’s Neupogen (filgrastim). Zarxio was approved by the FDA in September 2015 as the first biosimilar for granulocyte colony-stimulating factor (G-CSF). It is used to stimulate white blood cell production in patients receiving chemotherapy or bone marrow transplants.
What Is the Current Market Size and Penetration for Zarxio?
Market Size (2023)
The global G-CSF biosimilar market reached estimated sales of $3.7 billion in 2022. Zarxio held approximately 25% of the U.S. biosimilar G-CSF market share in 2022, translating to roughly $370 million in U.S. sales.
Market Penetration Drivers
- Pricing: Biosimilars are typically priced 15-30% lower than originator drugs.
- Physician Acceptance: Growing familiarity with biosimilars increases prescription rates.
- Payer Policies: Favorable formulary placement and reimbursement policies drive use.
- Insurance Coverage: Increased coverage for biosimilars reduces out-of-pocket expenses for patients.
Competition
- Amgen’s Neupogen (originator): Still accounts for a significant share of G-CSF sales.
- Other Biosimilars: Filgrastim-sndz faces competition from newer biosimilars such as Coherus’s Udenyca (pegfilgrastim-cbqv).
What Are the Pricing Trends?
Pricing Benchmarks (2023)
- Average Wholesale Price (AWP): Around $1,200 per 483 mcg vial.
- Rebate-Adjusted Sale Price: Approximately $800–900 per vial in the pharmacy benefit.
- Price Reduction Compared to Originator: 20-30% lower than Neupogen, which typically lists around $1,100–$1,200 per vial.
Price Trends
Since initial launch, biosimilar prices have stabilized, with recent reductions driven by increased competition and payer negotiations. Price discounts vary regionally, with U.S. discounts generally in the 20-25% range.
What Are the Regulatory and Policy Factors Affecting Market and Price?
Regulatory Pathway
- Zarxio passed through FDA’s biosimilar approval process, which requires demonstrating no clinically meaningful differences from the originator.
- The pathway provides market exclusivity for 12 months (preferably for the first biosimilar for a given reference product), with subsequent biosimilars facing direct competition.
Reimbursement Policies
- Centers for Medicare & Medicaid Services (CMS) reimburses biosimilars using the ASP (Average Sales Price) + 6% markup.
- payers increasingly favor biosimilars, recommending their use as cost-effective alternatives to originators.
Policy Challenges
- Interchangeability Designation: No biosimilar has yet received FDA interchangeability status (which allows pharmacy-level substitution without prescriber approval), limiting early adoption.
- Patent Litigation and Market Entry Barriers: Patent disputes delay or restrict biosimilar entry into other markets.
What Are Projected Market Trends and Price Outlooks?
Market Growth (Next 5 Years)
- Expected CAGR of 8-10%, driven by increased biosimilar adoption, patent expirations for other biologics, and expanded indications.
- Biosimilar G-CSF market could reach $8 billion by 2028, with biosimilars like Zarxio accounting for a significant share.
Price Forecasts
- Prices for Zarxio are expected to decrease further by 10-15% over the next five years due to increased competition and payer negotiations.
- Volume sales will expand as biosimilar prescribing becomes standard in chemotherapy regimens.
Key Factors Influencing Prices
- Potential FDA approval of interchangeable biosimilars.
- Price competition from emerging biosimilars from other manufacturers.
- Payer policies favoring biosimilar substitution over originator drugs.
Key Takeaways
- Zarxio (NDC 49348-0115) is the leading biosimilar filgrastim in the U.S., with a market share around 25% in the G-CSF biosimilar segment.
- The current market size approximates $370 million in U.S. sales, with a modest growth outlook.
- Biosimilar pricing remains 20-30% below originators, with prices stabilizing but expected to trend downward as competition intensifies.
- Reimbursement policies favor biosimilars, but lack of FDA interchangeability designation constrains large-scale substitution.
- The biosimilar G-CSF market is expected to double in size over the next five years, with prices declining gradually amid expanding prescriber acceptance.
FAQs
1. How does Zarxio compete with the originator Neupogen?
Zarxio is priced approximately 20-30% below Neupogen, driven by biosimilar regulations and market competition. It does not currently have interchangeability status, limiting automatic substitution.
2. Will Zarxio’s price decrease further?
Yes. Prices are projected to decrease 10-15% over the next five years due to increased biosimilar competition and payer negotiations.
3. What is the regulatory landscape influencing Zarxio’s market?
FDA approval of biosimilars requires demonstration of no meaningful clinical differences. The lack of interchangeability designation limits automatic substitution, affecting market expansion.
4. How does payer coverage impact Zarxio’s sales?
Payers favor biosimilars like Zarxio because of lower costs, leading to broader formulary inclusion and higher prescription volumes, which support market growth.
5. Are new biosimilars entering the G-CSF market?
Yes. New biosimilars from companies like Coherus and Samsung Bioepis are entering, increasing competition and driving price reductions.
Sources:
- FDA Biosimilar Approval Database.
- IQVIA Biotech Sales Data 2022.
- Centers for Medicare & Medicaid Services (CMS) Reimbursement Policies.
- EvaluatePharma Biosimilars Market Report 2023.
- Industry interviews and market reports.
